D Plan At Last

BRUSSELS—The European Economic Community’s R&D program of collaborative work on telecommunications and other advanced technologies is now poised to go ahead following a budgetary compromise between the British government and the rest of the EEC. Variously heralded in the British press as a retreat by Prime Minister Margaret Thatcher or a vindication of her demands for restraint, a 5.2 billion ECU ($6 billion), the Framework program for the next five years has been set by the EC

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

BRUSSELS—The European Economic Community’s R&D program of collaborative work on telecommunications and other advanced technologies is now poised to go ahead following a budgetary compromise between the British government and the rest of the EEC.

Variously heralded in the British press as a retreat by Prime Minister Margaret Thatcher or a vindication of her demands for restraint, a 5.2 billion ECU ($6 billion), the Framework program for the next five years has been set by the EC’s 12 nations. In what one senior diplomat described as a “nifty bit of drafting,” the governments also have agreed that plans for the program’s various projects will be drawn up as though the full 5.6 billion ECU budget agreed to in March by all but Britain were available.

Although the United Kingdom has refused formally to bridge the gap, the Thatcher government is expected to relent by the end of this year after ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies